GI
PGNX

Gradient Investments’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Gradient Investments’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,131
Closed -$26K – 1150
2018
Q3 		$26K Hold
4,131
– – ﹤0.01% 453
2018
Q2 		$33K Sell
4,131
-923
-18% -$7.05K ﹤0.01% 399
2018
Q1 		$38K Sell
5,054
-69,138
-93% -$460K ﹤0.01% 383
2017
Q4 		$441K Buy
74,192
+19,630
+36% +$119K 0.03% 195
2017
Q3 		$402K Buy
54,562
+17,394
+47% +$110K 0.03% 170
2017
Q2 		$252K Buy
+37,168
New +$274K 0.02% 210

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Gradient Investments's PGNX Position: Q4 2018 in Review

Gradient Investments sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2018, closing a stake of 4,131 shares — an estimated $26K sold.

Gradient Investments first reported a position in PGNX in Q2 2017 and held it in 6 quarters. The position peaked at $441K in Q4 2017. 150 funds tracked by Wall St. Rank hold PGNX as of Q4 2018.

  • Gradient Investments reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Gradient Investments sold 4,131 Progenics Pharmaceuticals Inc shares in Q4 2018, an estimated $26K.
  • Gradient Investments first reported a position in Progenics Pharmaceuticals Inc in Q2 2017 and held it in 6 quarters.
  • Gradient Investments's Progenics Pharmaceuticals Inc position peaked at $441K in Q4 2017.
  • 150 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2018.

Based on Gradient Investments's 13F filing for Q4 2018, filed 18 Jan 2019.